Viking Therapeutics, Inc. (NASDAQ:VKTX) CEO, Brian Lian, Ph.D., will deliver a corporate presentation at the 2018 BIO CEO & Investor Conference. It will be held February 12-13, 2018 in Marriott Marquis Hotel, New York. VKTX is a clinical-stage pharmaceutical company focusing on developing novel therapies for endocrine and metabolic disorders.
The company recently also announced closing of its public offering involving 12,650,000 shares of its common stock that also include 1,650,000 shares sold pursuant to the underwriters’ offering them full right or option to buy additional shares for covering over-allotments, at a public offering price of $5/share prior to deducting commissions, underwriting discounts and estimated offering expenses that are actually payable by the company.
Prior to the deduction of underwriting discounts and commissions and other estimates for offering expenses, the gross proceeds to VKTX from this particular offering is around $63.3 million. The company currently wants to use these net proceeds from the offering to the continued development of its VK5211, VK2809 and VK0214 programs.
Viking also intends to use these proceeds for general research and development, general corporate purposes and working capital.
Viking Therapeutics Recent Announcements
The biopharmaceutical company is focusing all its efforts on the development of best-in-class or first-in-class therapies for endocrine and metabolic disorders. The research and development activities of VKTX leverage its expertise in metabolism for developing novel therapeutics that can improve lives of the patients. The company has exclusive worldwide rights to a portfolio of 5 therapeutic programs in preclinical studies or clinical trials. These are based on the license for small molecules from Ligand Pharmaceuticals Incorporated.
VK5211 is a clinical program of the company. Its positive Phase 2 results were announced recently. Another clinical program from Viking a non-steroidal, orally available selective androgen receptor modulator or SARM which is under development for treating and preventing lean body mass loss in patients having undergone hip fracture surgery. VK2809 is a small molecule thyroid beta agonist in Phase 2 development of non-alcoholic fatty liver disease and hypercholesterolemia.